Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Perrigo
Perrigo
Activities:
Ingredients
Pharmaceutical
Dietary supplements
Active Nutrition
Food
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Manufacturing
Catalent client gets FDA approval for generic bronchodilator
Approval has marked the first generic metered-dose inhaler to be approved by the FDA in over twenty years and will now be scaled-up
Media
Hikma enters into licensing partnership with Perrigo in MENA
The partnership will provide significant collaboration opportunity
Finance
Mylan fails in US$26bn hostile takeover bid for Perrigo
Not enough shareholders supported the deal
Analysis
Operational cost savings for Perrigo UK
SP-4C weight checkers replace a manual sampling system
Finance
Perrigo to acquire OTC brands from GSK
In the areas of nicotine replacement therapy, cold and flu, and cold sore management
Drug Delivery
Perrigo acquires Patheon's Mexican operations for US$34m
Strengthening its capabilities with the addition of softgel manufacturing technology
Finance
Perrigo Board unanimously rejects unsolicited US$29bn bid from Mylan
Says it substantially undervalues the company and ignores key factors
Subscribe now